court decision on tirzepatide U.S. Judge Bars Copies of Weight Loss Drugs Can Courts Judge a Drug

Eli Lilly, the manufacturer of the GLP-1 / GIP agonist tirzepatide (Mounjaro, Zepbound) has announced the development of bimagrumab (LY3985863), an injected monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding

The combination of pharmacological appetite suppression with behavioral nutrition guidance produces synergistic effects that neither approach achieves independently

Understanding these mechanisms helps contextualise potential fertility implications of Wegovy and similar treatments

The STEP trial, which evaluated semaglutide for weight management, showed that consistent weekly administration produced sustained weight loss and metabolic improvements